Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.57 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2342552 | 0.89 | SIGMAR1 (0.55) | SIGMAR1CYP3A4HSD17B10OPRM1OPRL1 | |
| SCHEMBL15239000 | 0.83 | SIGMAR1 (0.55) | SIGMAR1CYP3A4HSD17B10OPRM1OPRL1 | |
| SCHEMBL17318844 | 0.82 | DRD2 (0.62) | SIGMAR1OPRM1TSHRKMT2ACYP2D6 | |
| SCHEMBL14774848 | 0.82 | DRD2 (0.50) | SIGMAR1MEN1ALDH1A1KMT2ADRD2 | |
| SCHEMBL18123312 | 0.80 | ALDH1A1 (0.63) | SIGMAR1CYP3A4HSD17B10OPRM1OPRL1 | |
| SCHEMBL11686136 | 0.80 | SIGMAR1 (0.68) | SIGMAR1CYP3A4HSD17B10OPRM1OPRL1 | |
| SCHEMBL2344239 | 0.80 | SIGMAR1 (0.56) | SIGMAR1CYP3A4ALDH1A1TSHRCYP2D6 | |
| SCHEMBL7952645 | 0.79 | SIGMAR1 (0.59) | SIGMAR1CYP3A4HSD17B10OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL11689691 | 0.79 | SIGMAR1 (0.66) | SIGMAR1CYP3A4HSD17B10OPRL1TMEM97 | |
| SCHEMBL15236204 | 0.79 | ALDH1A1 (0.77) | SIGMAR1CYP3A4HSD17B10OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503452-B2 | Antimicrobial compounds and methods | CURZA GLOBAL, LLC (US) | 2025-12-23 | — | — | US | disclosed |
| EP-4647431-A1 | COMPOUND AND METHOD FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Gan & lee Pharm Co., Ltd. (CN) | 2025-11-12 | — | — | EP | disclosed |
| WO-2024229393-A1 | HPK1 DEGRADERS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2024-11-07 | — | — | WO | disclosed |
| CN-115490699-B | Fused ring compound, pharmaceutical composition and application thereof | 成都海博为药业有限公司 | 2024-08-09 | — | — | CN | disclosed |
| WO-2024146617-A1 | COMPOUND AND METHOD FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR | 甘李药业股份有限公司 | 2024-07-11 | — | — | WO | disclosed |
| US-20240174674-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | APPLIED PHARMACEUTICAL SCIENCE, INC. (CN) | 2024-05-30 | — | — | US | disclosed |
| CN-114907338-B | Nitrogen-containing polycyclic condensed ring compound, pharmaceutical composition, preparation method and application thereof | 北京志健金瑞生物医药科技有限公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-4289428-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | Applied Pharmaceutical Science, Inc. (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289428-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | Applied Pharmaceutical Science, Inc. (CN) | 2023-12-13 | — | — | EP | disclosed |
| CN-111848577-B | N- (hetero) aryl-substituted heterocyclic derivatives useful in the treatment of diseases or conditions associated with the central nervous system | 克罗诺斯治疗有限公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-1182193-A1 | REMEDIES FOR NEUROPATHIC PAIN | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-27 | — | — | EP | disclosed |
| EP-1182192-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES HAVING ANTIARRHYTHMIC EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-27 | — | — | EP | disclosed |
| EP-0320032-B1 | Pyridizinamine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-01-18 | — | — | EP | disclosed |
| US-5231184-A | Viricide intermediate | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-07-27 | — | — | US | disclosed |
| US-5106973-A | Viricide intermediates | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-04-21 | — | — | US | disclosed |
| US-4992433-A | Viricides | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-02-12 | — | — | US | disclosed |
| EP-0152236-B1 | ARYLOXYMETHYLPYRROLIDINOLS AND PIPERIDINOLS HAVING ANTIDEPRESSANT, ANTIARHYTHMIC OR HYPOTENSIVE ACTIVITY | A.H. ROBINS COMPANY, INCORPORATED (US) | 1990-04-18 | — | — | EP | disclosed |
| EP-0320032-A1 | Pyridizinamine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-06-14 | — | — | EP | disclosed |
| EP-0152236-A2 | Aryloxymethylpyrrolidinols and piperidinols having antidepressant, antiarhythmic or hypotensive activity | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-08-21 | — | — | EP | disclosed |
| US-4508724-A | Aryloxymethylpyrrolidinols and piperidinols having antidepressant, antiarrhythmic or hypotensive activity | A. H. ROBINS COMPANY, INC. (US) | 1985-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174674-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | RET, WEE1, JAK2 | SIGMAR1 3656/4885CYP3A4 3154/4885HSD17B10 4149/4885 |
| US-12503452-B2 | Antimicrobial compounds and methods | MPO, NISCH, RPN2 | SIGMAR1 1380/4885CYP3A4 2721/4885HSD17B10 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.